# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: K153303   
B. Purpose for Submission: Clearance of new device   
C. Measurand: IgG class antibodies to West Nile virus   
D. Type of Test: ELISA for the qualitative detection of IgG class antibodies   
E. Applicant: EUROIMMUN US, INC.   
F. Proprietary and Established Names: EUROIMMUN Anti-West Nile Virus ELISA (IgG)

# G. Regulatory Information:

1. Regulation section: 21 CFR 866.3940 – West Nile virus serological reagents

2. Classification: Class II

3. Product code: NOP

4. Panel: Microbiology (83)

# H. Intended Use:

1. Intended use(s):

The EUROIMMUN Anti-West Nile Virus ELISA (IgG) is intended for the qualitative detection of IgG antibodies to West Nile virus in human serum and plasma ( $\mathrm { K } ^ { + }$ -EDTA, $\mathrm { L i } ^ { + }$ -heparin). This test is intended as an aid in the presumptive laboratory diagnosis of West Nile virus infection in patients with clinical symptoms consistent with meningitis/encephalitis, in conjunction with other laboratory and clinical findings. Positive results must be confirmed by the plaque reduction neutralization test (PRNT) or by using the current CDC guidelines for diagnosis of this disease.

The asssay characteristics have not been established for testing cord blood, neonates, prenatal screening, and general population screening of patients without symptoms of meningoencephalitis. This assay is not FDA cleared or approved for testing blood or plasma donors.

Warning: Cross-reactivity with IgG to Dengue, Chikungunya, Zika and Tick-borne Encephalitis viruses has been observed with the EUROIMMUN Anti-West Nile Virus ELISA (IgG). Reactive results must be reported with a caution statement regarding possible IgG cross-reactivity with other flaviviruses.

2. Indication(s) for use: Same as Intended Use

3. Special conditions for use statement(s): Not Applicable

4. Special instrument requirements: Not Applicable

# I. Device Description:

The EUROIMMUN Anti-West Nile Virus ELISA (IgG) test kit contains 12 microtiter strips each with 8 break-off reagent wells coated with West Nile virus antigen. Patient samples are diluted 1:101 in sample buffer, $1 0 0 \mu \mathrm { l }$ of each diluted patient sample and pre-diluted controls and the calibrator are added to the antigen coated microtiter wells and incubated for 60 minutes at $3 7 ^ { \circ } \mathrm { C }$ . After incubation, the microtiter well strips are washed 3 times with wash buffer to remove unbound antibodies and $1 0 0 \mu \mathrm { l }$ of the anti-human $\mathrm { I g G }$ horseradish peroxidase (HRP) enzyme conjugate reagent is added to each microtiter well. After an additional 30 minutes incubation at room temperature, the microtiter wells are again washed 3 times with wash buffer to remove any unbound enzyme conjugate and $1 0 0 \mu \mathrm { l }$ of the chromogen substrate is added. The strips are incubated for 15 minutes at room temperature and $1 0 0 \mu \mathrm { l }$ stop solution is added. The microtiter plates are placed in an ELISA reader and read at a wavelength of $4 5 0 \mathrm { n m }$ and a reference wavelength of between $6 2 0 \mathrm { n m }$ and $6 5 0 \mathrm { n m }$ within 30 minutes.

The antigen source in the EUROIMMUN Anti-West Nile Virus ELISA (IgG) is a recombinant, detergent-extracted glycoprotein E of West Nile virus from the membrane fraction of human cells

# J. Substantial Equivalence Information:

1. Predicate device name(s): Focus Diagnostics West Nile Virus IgG DxSelect™

2. Predicate 510(k) number(s): K031953

3. Comparison with predicate:

Similarities   

<table><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">New DeviceEUROIMMUN Anti-West NileVirus ELISA (IgG) (K153303)</td><td colspan="1" rowspan="1">Predicate DeviceFocus Diagnostics West Nile VirusIgG DxSelectTM ELISA (K031953)</td></tr><tr><td colspan="1" rowspan="1">Intended use</td><td colspan="1" rowspan="1">The EUROIMMUN Anti-WestNile Virus ELISA (IgG) isintended for the qualitativedetection of IgG antibodies toWest Nile virus in human serumand plasma (K+-EDTA, Li+-heparin). This test is intended asan aid in the presumptivelaboratory diagnosis of West Nilevirus infection in patients withclinical symptoms consistent withmeningitis/encephalitis, inconjunction with other laboratoryand clinical findings. Positiveresults must be confirmed byplaque reduction neutralization test(PRNT) or by using the currentCDC guidelines for diagnosis ofthis disease.</td><td colspan="1" rowspan="1">The Focus Diagnostics West NileVirus IgG DxSelectTM is intendedfor qualitatively detecting IgGantibodies to West Nile virus inhuman serum. In conjunction withthe Focus Diagnostics West NileVirus IgM Capture DxSelect™M,the test is indicated for testingpersons having symptoms ofmeningioencephalitis, as an aid inthe presumptive laboratorydiagnosis of West Nile virusinfection. Positive results must beconfirmed by neutralization test, orby using the current CDCguidelines for diagnosing WestNile encephalitis. This test is notintended for self-testing, and thistest is not FDA cleared norapproved for testing blood orplasma donors. Assay performancecharacteristics have not beenestablished for automatedinstruments.</td></tr><tr><td colspan="1" rowspan="1">Assay format</td><td colspan="1" rowspan="1">Qualitative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Technology</td><td colspan="1" rowspan="1">ELISA</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay platform</td><td colspan="3" rowspan="1">96-well microtiter plates</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Antigen</td><td colspan="3" rowspan="1">Coated on microtiter plate</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibrators andControls</td><td colspan="3" rowspan="1">1 calibrator (cut-off)2 controls: 1 positive; 1 negative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Conjugate</td><td colspan="3" rowspan="1">Anti-human IgG (rabbit) labelledwith horseradish peroxidase</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Substrate</td><td colspan="3" rowspan="1">TMB</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Wash buffer</td><td colspan="3" rowspan="1">10x concentrate</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Serum sampledilution</td><td colspan="3" rowspan="1">1:101</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Procedure</td><td colspan="3" rowspan="1">Sample incubation with micro-well antigen coated plate, followedby a wash step, incubation with ananti-human IgG enzymeconjugate; wash step, incubationwith substrate; stopping of thereaction with stop solution,photometric reading.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="5" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="3" rowspan="1">New DeviceEUROIMMUN Anti-West NileVirus ELISA (IgG) (K153303)</td><td colspan="1" rowspan="1">Predicate DeviceFocus Diagnostics West Nile VirusIgG DxSelectTM ELISA (K031953)</td></tr><tr><td colspan="1" rowspan="1">Antigen</td><td colspan="3" rowspan="1">Recombinant, detergent-extractedglycoprotein E of West Nile virusfrom the membrane fraction ofhuman cells, inactivated usinghigh temperatures and gammaradiation; effectiveness ofinactivation tested by culture</td><td colspan="1" rowspan="1">Recombinant West Nile virusantigen</td></tr><tr><td colspan="1" rowspan="1">Stop solution</td><td colspan="3" rowspan="1">0.5 M sulphuric acid</td><td colspan="1" rowspan="1">1 M sulfuric acid</td></tr><tr><td colspan="1" rowspan="1">Reagent preparation</td><td colspan="3" rowspan="1">All reagents, calibrator andcontrols are ready to use, exceptfor the wash buffer.</td><td colspan="1" rowspan="1">Calibrator and controls requiredilution before use.</td></tr><tr><td colspan="1" rowspan="1">Sample matrix</td><td colspan="3" rowspan="1">Serum or plasma (EDTA, Li-heparin),</td><td colspan="1" rowspan="1">Serum</td></tr><tr><td colspan="1" rowspan="1">Reported results</td><td colspan="3" rowspan="1">Ratio</td><td colspan="1" rowspan="1">Index</td></tr><tr><td colspan="1" rowspan="2">Cut-off levels</td><td colspan="3" rowspan="2">Ratio         Result&lt;0.8          negative≥0.8 to &lt;1.1borderline≥1.1           positive</td><td colspan="1" rowspan="2">Index                 Result&lt; 1.30                negative≥ 1.30 to &lt; 1.50   equivocal≥ 1.50                positive</td></tr><tr><td colspan="1" rowspan="1">negative</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Class II Special Controls Guidance Document: Serological Reagents for the Laboratory

Diagnosis of West Nile Virus, October 30, 2003.

# L. Test Principle:

In the first reaction step, diluted patient samples, calibrators and controls are incubated in the wells. Anti-West Nile virus antibodies will bind to the antigens coated in the microtiter wells. The wells are washed to remove any unbound proteins and non-specific antibodies. In a second reaction step, rabbit anti-human IgG HRP enzyme conjugate is added to each well. The enzyme conjugate will bind to any wells that have human IgG bound to the West Nile virus antigen. The wells are washed to remove any unbound HRP enzyme conjugate. Enzyme substrate (3,3,5,5 tetramethylbenzidine (TMB)) is then added. If the HRP enzyme is present in the well, the HRP enzyme will react with the TMB substrate and produce a blue color indicating a positive result. After an additional incubation time to allow the color development, a stop solution is added which turns the color from blue to yellow and inhibits further color development to allow for a stable spectrophotometric reading. The test strips are placed in a microplate reader and the optical density of the color is measured. The amount of antigen specific bound antibody is proportional to the color intensity.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/ Repeatability:

The repeatability of the EUROIMMUN Anti-West Nile Virus ELISA (IgG) was investigated by testing of a panel of 7 members prepared using natural patient samples seropositive at different levels of antibody. The inter-assay repeatability is based on 42 determinations per sample performed in 14 different runs on 7 different days (with 2 runs per day and 3 replicates per run). The data from the repeatability study is presented in the table below.

Precision/Repeatability   

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>MeanRatio</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Within Day</td><td rowspan=1 colspan=2>Between Days</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>7.4%</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>13.2%</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>13.3%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>11.7%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>6.9%</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>13.6%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>4.2%</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>9.7%</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>9.7%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>10.4%</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>10.4%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>4.2%</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>6.7%</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>6.7%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>6.1%</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>6.1%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>5.5%</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>6.6%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>5.7%</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>6.1%</td></tr></table>

# b. Reproducibility:

The reproducibility of the EUROIMMUN Anti-West Nile Virus ELISA (IgG) was investigated by testing of a panel of 7 members prepared using natural patient samples seropositive at different levels of antibody. The reproducibility is based on 60 determinations per sample performed at 3 different sites (in-house, and 2 external laboratories) for 5 days with 2 runs per day and 2 replicates per run. The data from the reproducibility study is presented in the table below.

Reproducibility   

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>MeanRatio</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Within-Day</td><td rowspan=1 colspan=2>Between-Days</td><td rowspan=1 colspan=2>Between-Sites</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>14.1%</td><td rowspan=1 colspan=1>0.011</td><td rowspan=1 colspan=1>15.0%</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>6.4%</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>0.012</td><td rowspan=1 colspan=1>16.3%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.072</td><td rowspan=1 colspan=1>11.0%</td><td rowspan=1 colspan=1>0.096</td><td rowspan=1 colspan=1>14.7%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.063</td><td rowspan=1 colspan=1>9.7%</td><td rowspan=1 colspan=1>0.096</td><td rowspan=1 colspan=1>14.7%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.062</td><td rowspan=1 colspan=1>8.0%</td><td rowspan=1 colspan=1>0.075</td><td rowspan=1 colspan=1>9.8%</td><td rowspan=1 colspan=1>0.017</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.043</td><td rowspan=1 colspan=1>5.7%</td><td rowspan=1 colspan=1>0.077</td><td rowspan=1 colspan=1>10.1%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.070</td><td rowspan=1 colspan=1>8.3%</td><td rowspan=1 colspan=1>0.098</td><td rowspan=1 colspan=1>11.6%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.069</td><td rowspan=1 colspan=1>8.1%</td><td rowspan=1 colspan=1>0.098</td><td rowspan=1 colspan=1>11.6%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.089</td><td rowspan=1 colspan=1>7.8%</td><td rowspan=1 colspan=1>0.119</td><td rowspan=1 colspan=1>10.5%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.079</td><td rowspan=1 colspan=1>7.0%</td><td rowspan=1 colspan=1>0.119</td><td rowspan=1 colspan=1>10.5%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.211</td><td rowspan=1 colspan=1>9.7%</td><td rowspan=1 colspan=1>0.211</td><td rowspan=1 colspan=1>9.7%</td><td rowspan=1 colspan=1>0.060</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>0.219</td><td rowspan=1 colspan=1>10.1%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>0.405</td><td rowspan=1 colspan=1>9.4%</td><td rowspan=1 colspan=1>0.436</td><td rowspan=1 colspan=1>10.1%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.161</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>0.436</td><td rowspan=1 colspan=1>10.1%</td></tr></table>

c. Linearity/assay reportable range: Not applicable   
d. Traceability, Stability, Expected values (controls, calibrators, or methods): Not applicable   
e. Detection limit: Not applicable

# f. Analytical specificity/Cross-reactivity:

Cross-reactivity was investigated using 910 serologically characterized seropositive specimens from patients with diseases other than West Nile virus. Each of the specimens included in the study was characterized with respect to disease state prior to analysis of the specimens with the EUROIMMUN Anti-West Nile Virus ELISA (IgG). Cross-reactivity across the flavivirus group is common (e.g., St. Louis encephalitis, Dengue 1, 2, 3 & 4; Murray Valley encephalitis, Japanese encephalitis, and Yellow fever viruses) as well as persons vaccinated for flaviviruses.

Cross-reactivity   

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Anti-West Nile Virus ELISA (IgG)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Negative</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Anti-Adenovirus</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Anti-Barmah Forest virus</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Anti-Borrelia burgdorferi</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>94.4%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Anti-Chikungunya virus</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>68.1%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Anti-Chlamydia pneum.</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Anti-CMV</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>Anti-Dengue virus</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>13.8%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>Anti-EBV</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>96.7%</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>Anti-Hanta virus</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Anti-Hepatitis virus</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>Anti-Helicobacter pylori</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>Anti-HSV-1</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>94.9%</td></tr><tr><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>Anti-Influenza A</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>Anti-Influenza B</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>Anti-Leptospira</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>Malaria/anti-Plasmodium falciparum</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>Anti-Measles virus</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>Anti-Mumps virus</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>Anti-Mycoplasma pneumoniae</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>Anti-Parainfluenza types 1-4</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>Anti-Polio virus</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>97.3%</td></tr><tr><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>Anti-Ross River virus</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>95.0%</td></tr><tr><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>Anti-RSV</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>Anti-Rubella virus</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>Anti-TBE virus</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>72.0%</td></tr><tr><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>Anti-Toxoplasma gondii</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>Anti-VZV</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>Anti-West Nile Virus</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>Yellowfever virus immunization</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>Anti-Zika virus</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>Rheumatoid arthritis/polyarthritis/anti-CCP</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>Anti-Rheumatoid factor</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>97.3%</td></tr><tr><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>Anti-nuclear autoantibodies</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>97.0%</td></tr><tr><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>ANCA-associated small vesselvasculitides/ANCA</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>Celiac disease/anti-endomysium</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>Plasma cell myeloma</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>100.0%</td></tr></table>

# g. Interference:

Hemolytic, lipemic and icteric samples showed no influence on the result up to a concentration of $1 0 0 0 \mathrm { m g / d L }$ for hemoglobin, $2 0 0 0 \mathrm { m g / d L }$ for triglycerides and 40 $\mathrm { m g / d L }$ for bilirubin in testing with the EUROIMMUN Anti-West Nile Virus ELISA (IgG). Interferences from high protein (albumin), cholesterol, and intralipids were not investigated.

h. Assay cut-off:

The assay cut-off and borderline range was established based on a ROC analysis of 18 sera from clinically characterized positive West Nile virus patiens and 150 sera from normal healthy individuals from a non-endemic region.

The ROC analysis demonstrated optimal sensitivity $( 1 0 0 . 0 \% )$ and specificity $( 1 0 0 . 0 \% )$ at the OD value of 0.475. The calibrator was established at this cut-off OD.

The borderline range of ratio 0.8 to ratio 1.1 was established to cover at least $9 8 \%$ of the negative samples (148 of 150 samples) in the negative range.

Using the cut-off ratio 1.0 and borderline range of ratio 0.8 to 1.1 with the positive and negative groups mentioned above, the EUROIMMUN Anti-West Nile Virus ELISA (IgG) showed a sensitivity of $1 0 0 . 0 \%$ ( $9 5 \%$ C.I.: 81.5 – 100.0%) with a specificity of $9 8 . 7 \%$ ( $9 5 \%$ C.I.: 95.3 – 99.8).

2. Comparison studies:

a. Method comparison with predicate device: The EUROIMMUN Anti-West Nile Virus ELISA $\mathrm { ( I g G ) }$ was compared with two reference assays: The predicate device Focus Diagnostics West Nile Virus IgG Capture DxSelect™ (K153303) and the plaque reduction neutralization test (PRNT).

b. Matrix comparison:

Serum vs plasma comparison: The usability of plasma was investigated using serum paired with the corresponding plasma (EDTA, Li-heparin). Passing-Bablok regression was calculated for the comparison of serum to plasma. The regression equations indicated equivalence of serum and the corresponding plasma matrices. Coefficients of determination were found to be above 0.975 and $\%$ recovery compared to serum was in the range of 92 to $109 \%$ (serum $= 1 0 0 \%$ ).

Serum vs Plasma Comparison   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>EDTA plasma</td><td rowspan=1 colspan=1>Li-heparin plasma</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Concentration range (serum)</td><td rowspan=1 colspan=1>Ratio 0.6 - 4.1</td><td rowspan=1 colspan=1>Ratio 0.6 - 4.1</td></tr><tr><td rowspan=1 colspan=1>Concentration range (plasma)</td><td rowspan=1 colspan=1>Ratio 0.6 - 4.1</td><td rowspan=1 colspan=1>Ratio 0.6 - 4.1</td></tr><tr><td rowspan=1 colspan=1>Regression equation(y = Plasma, x = Serum)</td><td rowspan=1 colspan=1>y = -0.01 + 1.02x</td><td rowspan=1 colspan=1>y = 0.04 + 0.96x</td></tr><tr><td rowspan=1 colspan=1>95% C.I. of intercept</td><td rowspan=1 colspan=1>-0.05 - 0.02</td><td rowspan=1 colspan=1>-0.11 - 0.15</td></tr><tr><td rowspan=1 colspan=1>95% C.I. of slope</td><td rowspan=1 colspan=1>0.99 - 1.05</td><td rowspan=1 colspan=1>0.89 - 1.10</td></tr><tr><td rowspan=1 colspan=1>Coefficient of determination R2</td><td rowspan=1 colspan=1>0.9983</td><td rowspan=1 colspan=1>0.9759</td></tr><tr><td rowspan=1 colspan=1>Mean % recovery</td><td rowspan=1 colspan=1>101 %</td><td rowspan=1 colspan=1>100 %</td></tr><tr><td rowspan=1 colspan=1>Range of % recovery</td><td rowspan=1 colspan=1>98 - 105 %</td><td rowspan=1 colspan=1>92 - 109 %</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity: Not Applicable

$b$ . Clinical specificity: Not Applicable

c. Other clinical supportive data (when a. and b. are not applicable):

# Clinical Study I:

A prospective clinical study was performed with 152 samples from patients suspected of West Nile Virus infection collected at hospitals and clinics across the US in year 2015. The panel consisted of 81 men and 71 women; the ages ranged from 6 to 85 years with a mean age of 49 years. Each specimen was tested at one internal and two external sites with the EUROIMMUN Anti-West Nile Virus ELISA (IgG) in parallel with the predicate assay. The average of three results for each clinical specimen tested at three sites was considered to calculate the positive percent agreement and negative percent agreement between the EUROIMMUN Anti-West Nile Virus ELISA (IgG) vs the predicate assay. The following results were obtained.

Clinical Study I: EUROIMMUN Anti-West Nile Virus ELISA $\underline { { ( \mathrm { I g G } ) } }$ against predicate   

<table><tr><td rowspan=2 colspan=2>Serumn= 152</td><td rowspan=1 colspan=3>Predicate Assay</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Borderline</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=3 colspan=1>EUROIMMUN Anti-WestNile Virus ELISA (IgG)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Borderline</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>101</td></tr></table>

<table><tr><td>Positive Agreement</td><td>93.3% (42/45)</td><td>95% C.I.</td><td>81.7-98.6%</td></tr><tr><td>Negative Agreement</td><td>94.39% (101/107)</td><td>95% C.I.</td><td>88.2-97.9%</td></tr></table>

Of the 45 presumptive positives by the predicate device, 27 samples were further tested by PRNT and the EUROIMMUN Anti-West Nile Virus ELISA (IgG). The results are shown below.

Clinical Study I: EUROIMMUN Anti-West Nile Virus ELISA (IgG) against PRNT   

<table><tr><td rowspan=2 colspan=2>Serumn= 27</td><td rowspan=1 colspan=3>PRNT Results</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Borderline</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=3 colspan=1>EUROIMMUN Anti-WestNile Virus ELISA (IgG)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Borderline</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

Sensitivity 92.6% (25/27) 95% C.I. $7 5 . 7 \mathrm { - } 9 9 . 1 \%$

# Clinical Study II:

A study was performed at a clinical laboratory in the midwest, with 401 serum samples collected prospectively from patients suspected of infection with West Nile virus. The patients consisted of 195 men and 206 women; the ages ranged from 3 to 102 years with a mean age of 47 years. The samples were tested with the EUROIMMUN Anti-West Nile Virus ELISA (IgG) in parallel with the predicate ELISA.

Clinical Study II: EUROIMMUN Anti-West Nile Virus ELISA $( \mathrm { I g G } )$ against predicate   

<table><tr><td rowspan=2 colspan=2>Serumn = 401</td><td rowspan=1 colspan=3>Predicate Assay</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Borderline</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=3 colspan=1>EUROIMMUN Anti- WestNile Virus ELISA (IgG)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Borderline</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>352</td></tr></table>

Positive Agreement 95.6% (43/45) 95% C.I. 84.9-99.5% C Negative Agreement $9 8 . 9 \%$ (352/356) 95% C.I. 97.1-99.7%

# Clinical Study III:

A retrospective clinical study was performed in cooperation with the Robert Koch Institute (RKI), Berlin, Germany with 295 serum samples that included 200 samples from major outbreaks of West Nile fever in South Africa in 1974 and 1984. The samples were tested by PRNT and the EUROIMMUN Anti-West Nile Virus ELISA $\mathrm { ( I g G ) }$ . The results are shown below.

Clinical Study II: EUROIMMUN Anti-West Nile Virus ELISA $\mathrm { ( I g G ) }$ against PRNT   

<table><tr><td rowspan=2 colspan=2>Serumn = 295</td><td rowspan=1 colspan=2>PRNT Results</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=3 colspan=1>EUROIMMUN Anti- WestNile Virus ELISA (IgG)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>194</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Borderline</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>97</td></tr></table>

Sensitivity 99.5% (194/195) 95% C.I. 97.29-100.0% Specificity 97.0% (97/100) 95% C.I. $9 1 . 5 – 9 9 . 4 \%$

4. Clinical cut-off:

Not Applicable

5. Expected values:

Euroimmun assessed reactivity with 553 samples prospectively collected from patients in the US. The samples consisted of $50 \%$ females and $50 \%$ males The range of positivity of different populations from the US prospective studies with the EUROIMMUN Anti-West Nile Virus ELISA (IgG) test kit are presented below.

Expected Values from US Studies   

<table><tr><td rowspan=1 colspan=1>Age</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Borderline</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>% Positive</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>0-9</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.0 - 20.6%</td></tr><tr><td rowspan=1 colspan=1>10-19</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>6.3% (2/32)</td><td rowspan=1 colspan=1>0.8 - 20.8%</td></tr><tr><td rowspan=1 colspan=1>20-29</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>7.6% (5/66)</td><td rowspan=1 colspan=1>2.5 - 16.8%</td></tr><tr><td rowspan=1 colspan=1>30-39</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>12.8% (11/86)</td><td rowspan=1 colspan=1>6.6 - 21.7%</td></tr><tr><td rowspan=1 colspan=1>40-49</td><td rowspan=1 colspan=1>89</td><td rowspan=1 colspan=1>76</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>13.5% (12/89)</td><td rowspan=1 colspan=1>7.2 - 22.4%</td></tr><tr><td rowspan=1 colspan=1>50-59</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>19.0% (19/100)</td><td rowspan=1 colspan=1>11.8 - 28.1 %</td></tr><tr><td rowspan=1 colspan=1>60+</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>25.0% (41/164)</td><td rowspan=1 colspan=1>18.6 - 32.3%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>553</td><td rowspan=1 colspan=1>455</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>16.3% (90/455)</td><td rowspan=1 colspan=1>13.3 - 19.6%</td></tr></table>

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.